22:43:34 EDT Sat 28 May 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:LEXX from 2021-05-28 to 2022-05-27 - 91 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2022-05-26 08:30U:LEXXNews ReleaseLexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space
2022-05-25 08:30U:LEXXNews ReleaseLexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space
2022-04-21 09:06U:LEXXNews ReleaseLexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
2022-04-21 09:05U:LEXXNews ReleaseLexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
2022-04-19 09:06U:LEXXNews ReleaseLexaria Commences Multi-Week Human Clinical Hypertension Study
2022-04-19 09:05U:LEXXNews ReleaseLexaria Commences Multi-Week Human Clinical Hypertension Study
2022-04-14 08:47U:LEXXNews ReleaseLexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
2022-04-14 08:46U:LEXXNews ReleaseLexarias Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
2022-04-12 09:11U:LEXXNews ReleaseLexaria Provides Update on Human Nicotine Study NIC-H22-1
2022-04-12 09:11U:LEXXNews ReleaseLexaria Provides Update on Human Nicotine Study NIC-H22-1
2022-04-11 10:55U:LEXXSEDAR Interim Financial StatementsSEDAR MD & A
2022-04-11 09:01U:LEXXNews ReleaseLexaria Begins New Nicotine Formulation Creation and Evaluation Program
2022-04-11 09:01U:LEXXNews ReleaseLexaria Begins New Nicotine Formulation Creation and Evaluation Program
2022-03-15 14:11U:LEXXNews ReleaseLexaria Begins DehydraTECH-CBD Epilepsy Research Program
2022-03-15 14:06U:LEXXNews ReleaseLexaria Begins DehydraTECH-CBD Epilepsy Research Program
2022-03-08 09:16U:LEXXNews ReleaseLexaria Granted Important New Oral Nicotine Patent
2022-03-08 09:16U:LEXXNews ReleaseLexaria Granted Important New Oral Nicotine Patent
2022-02-02 09:27U:LEXXNews ReleaseLexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
2022-02-02 09:26U:LEXXNews ReleaseLexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
2022-01-27 09:37U:LEXXNews ReleaseLexaria Provides Annual Letter From the CEO
2022-01-27 09:36U:LEXXNews ReleaseLexaria Provides Annual Letter From the CEO
2022-01-20 08:00U:LEXXNews ReleaseIBN (InvestorBrandNetwork) Announces EDGE Podcast Interview with Lexaria Bioscience Corp. CEO Chris Bunka
2022-01-18 09:32U:LEXXNews ReleaseLexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
2022-01-18 09:26U:LEXXNews ReleaseLexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
2022-01-14 19:34U:LEXXSEDAR Interim Financial StatementsSEDAR MD & A
2021-12-29 11:20U:LEXXNews ReleaseLexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
2021-12-29 11:16U:LEXXNews ReleaseLexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
2021-12-16 14:50U:LEXXNews ReleaseLexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
2021-12-16 14:46U:LEXXNews ReleaseLexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
2021-12-14 11:54U:LEXXNews ReleaseLexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
2021-12-14 11:52U:LEXXNews ReleaseLexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
2021-12-08 07:31U:LEXXNews ReleaseLexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
2021-12-08 07:31U:LEXXNews ReleaseLexaria's DehydraTECH(TM)-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
2021-12-06 16:45U:LEXXNews ReleaseLexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference
2021-12-01 20:24U:LEXXSEDAR Annual Information FormSEDAR Annual Information Form
2021-11-29 16:21U:LEXXSEDAR MD & ASEDAR MD & A
2021-11-29 16:10U:LEXXSEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2021-11-10 09:02U:LEXXNews ReleaseLexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
2021-11-10 09:01U:LEXXNews ReleaseLexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
2021-11-03 07:32U:LEXXNews ReleaseLexaria Announces Ambitious New Hypertension Study HYPER-H21-4
2021-11-03 07:31U:LEXXNews ReleaseLexaria Announces Ambitious New Hypertension Study HYPER-H21-4
2021-11-01 09:02U:LEXXNews ReleaseLexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
2021-11-01 09:01U:LEXXNews ReleaseLexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
2021-10-20 08:31U:LEXXNews ReleaseLexaria THC Test Results Come in as MORE Act Gains Momentum in Congress
2021-10-13 11:02U:LEXXNews ReleaseLexaria's Technology Proven to Deliver Oral THC More Effectively
2021-10-13 11:01U:LEXXNews ReleaseLexaria's Technology Proven to Deliver Oral THC More Effectively
2021-10-12 08:17U:LEXXNews ReleaseIBN (InvestorBrandNetwork) Announces Latest Episode of Stock2Me Podcast Featuring Lexaria Bioscience Corp. Chairman & CEO Chris Bunka
2021-10-05 10:49U:LEXXNews ReleaseDehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete
2021-10-05 09:11U:LEXXNews ReleaseLexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
2021-10-05 09:06U:LEXXNews ReleaseLexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
2021-09-21 07:50U:LEXXNews ReleaseLexston Life Sciences Corp. Acquires Zenalytic Laboratories Ltd.
2021-09-09 07:06U:LEXXNews ReleaseLexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-09 07:06U:LEXXNews ReleaseLexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-08 07:06U:LEXXNews ReleaseLexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
2021-09-08 07:05U:LEXXNews ReleaseLexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
2021-09-07 07:08U:LEXXNews ReleaseLexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
2021-09-07 07:06U:LEXXNews ReleaseLexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
2021-08-17 08:31U:LEXXNews ReleaseWinning Formulation; Lexaria Takes Strategic Aim at High Value Hypertension and Antiviral Therapeutics Markets with Robust Drug Delivery Technology
2021-07-29 07:06U:LEXXNews ReleaseLexaria's DehydraTECH-CBD Lowers Blood Pressure
2021-07-29 07:05U:LEXXNews ReleaseLexaria's DehydraTECH-CBD Lowers Blood Pressure
2021-07-28 07:07U:LEXXNews ReleaseDehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
2021-07-28 07:06U:LEXXNews ReleaseDehydraTECH(TM) - Enabled Consumer Products Now Available in Over 7,000 Stores
2021-07-27 07:16U:LEXXNews ReleaseLexaria Completes Dosing in Human Clinical Study HYPER-H21-2
2021-07-27 07:16U:LEXXNews ReleaseLexaria Completes Dosing in Human Clinical Study HYPER-H21-2
2021-07-26 14:43U:LEXXNews ReleaseLexaria Receives US$3,817,643 From Warrant Exercises
2021-07-26 14:41U:LEXXNews ReleaseLexaria Receives US$3,817,643 From Warrant Exercises
2021-07-22 07:05U:LEXXNews ReleaseLexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
2021-07-22 07:05U:LEXXNews ReleaseLexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
2021-07-21 08:16U:LEXXNews ReleaseLexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
2021-07-21 07:05U:LEXXNews ReleaseLexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
2021-07-15 18:52U:LEXXSEDAR Interim Financial StatementsSEDAR MD & A
2021-07-15 07:07U:LEXXNews ReleaseLexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
2021-07-15 07:06U:LEXXNews ReleaseLexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council
2021-07-13 07:11U:LEXXNews ReleaseLexaria Receives Patent Protection in Japan
2021-07-13 07:06U:LEXXNews ReleaseLexaria Receives Patent Protection in Japan
2021-07-05 08:02U:LEXXNews ReleaseLexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
2021-07-05 08:00U:LEXXNews ReleaseLexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
2021-06-29 16:06U:LEXXNews ReleaseLexaria Announces 2021 Annual Meeting Results
2021-06-29 16:05U:LEXXNews ReleaseLexaria Announces 2021 Annual Meeting Results
2021-06-28 08:35U:LEXXNews ReleaseLife Sciences Companies Investor Presentations Now Available for On-Demand Viewing
2021-06-21 08:35U:LEXXNews ReleaseVirtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
2021-06-17 08:31U:LEXXNews ReleaseLexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
2021-06-15 07:06U:LEXXNews ReleaseLexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
2021-06-15 07:06U:LEXXNews ReleaseLexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
2021-06-09 07:01U:LEXXNews ReleaseLexaria Provides Progress Report on Six R&D Programs
2021-06-09 07:01U:LEXXNews ReleaseLexaria Provides Progress Report on Six R&D Programs
2021-06-08 16:56U:LEXXNews ReleaseLexaria Announces Issuance of Options
2021-06-07 07:01U:LEXXNews ReleaseLexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
2021-06-07 07:01U:LEXXNews ReleaseLexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
2021-06-03 07:06U:LEXXNews ReleaseLexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
2021-06-03 07:02U:LEXXNews ReleaseLexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus